Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 842 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 842 shares of the stock in a transaction on Friday, March 28th. The shares were sold at an average price of $50.00, for a total value of $42,100.00. Following the sale, the director now directly owns 278,945 shares in the company, valued at $13,947,250. This trade represents a 0.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Pro-Dex Trading Up 2.8 %

NASDAQ:PDEX opened at $49.58 on Tuesday. The company has a market cap of $161.68 million, a PE ratio of 24.67 and a beta of 0.68. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33. The company has a 50 day simple moving average of $40.31 and a two-hundred day simple moving average of $40.26. Pro-Dex, Inc. has a 12 month low of $16.84 and a 12 month high of $59.60.

Pro-Dex (NASDAQ:PDEX) last posted its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Research analysts forecast that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

Institutional Investors Weigh In On Pro-Dex

Several hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC boosted its holdings in shares of Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after buying an additional 1,028 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Pro-Dex in the fourth quarter worth approximately $202,000. Trexquant Investment LP purchased a new position in shares of Pro-Dex during the 4th quarter worth $252,000. Integrated Quantitative Investments LLC purchased a new position in shares of Pro-Dex during the 4th quarter worth $254,000. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Pro-Dex during the 4th quarter valued at $255,000. Hedge funds and other institutional investors own 15.28% of the company’s stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.